ARTICLE | Product Development
AZ, Daiichi set new standard in HER2-low breast cancer with Enhertu data
HER2-targeted ADC doubles PFS in Phase III breast cancer study, provides broader proof of concept for the therapeutic modality
June 5, 2022 3:54 PM UTC
Enhertu emerged as ASCO’s clear winner on Sunday with Phase III data that not only move the already successful HER2-targeted antibody-drug conjugate into a large indication lacking targeted therapies, but also change the way breast cancers will be defined.
AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Daiichi Sankyo Co. Ltd. (Tokyo:4568) reported at the American Society of Clinical Oncology (ASCO) conference that Enhertu fam-trastuzumab deruxtecan-nxki doubled progression-free survival to 10.1 months from 5.4 months with standard of care, for previously treated HR-positive, HER2-negative breast cancer patients (HR=0.51; p<0.001)...